Immunic appoints Patrick Walsh as Chief Business Officer; $380K salary, 120K options

IMMUNIC, INC.

Patrick Walsh appointed Chief Business Officer, effective Oct 14, 2021.
Base salary $380,000, signing bonus $60,000, options for 120,000 shares.
Options vest 25% on first anniversary, then monthly over 36 months; target bonus min 35%.
Severance: 12 months' base salary on termination without cause; 33% equity vesting (100% near change of control).
Previously VP Business Development at Akebia Therapeutics; earlier roles at AVEO, Capgemini, Leerink.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Patrick Walsh

Chief Business Officer

IMUX · IMMUNIC, INC.

Effective: 2021-10-14
Filed: October 15, 2021, 7:59 PM ET

On October 14, 2021, the board of directors (the “Board”) of Immunic, Inc. (the “Company”) appointed Patrick Walsh as the Chief Business Officer, effective October 14, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Patrick Walsh was appointed as Chief Business Officer at IMMUNIC, INC..

Action: appointed
Role: Chief Business Officer

Exact text from the filing

On October 14, 2021, the board of directors (the “Board”) of Immunic, Inc. (the “Company”) appointed Patrick Walsh as the Chief Business Officer, effective October 14, 2021.

View on SEC.gov

IMMUNIC, INC. filing history →

Source: SEC EDGAR

accession 0001193805-21-001455

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.